Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Oct 13;21:719. doi: 10.1186/s12967-023-04585-7

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2023

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

PMC Copyright notice

Fig. 3 — Expression of vimentin in PDCs after inhibition of SUMOylation and ubiquitination. A Cytoplasmic vimentin expression in Hct116 and LoVo PDCs after siRNA-SUMO1 transfection. B Nuclear vimentin expression levels in Hct116 and LoVo PDCs after siRNA-SUMO1 transfection. C Total SUMO2/3 expression levels in Hct116 PDCs after transfection with siRNA-SUMO2/3 (275 471, 315 744, 498 814) transfection. D Total vimentin expression levels in LoVo PDCs after siRNA-SUMO2/3 (275 471, 315 744, 498 814) transfection. E Cytoplasmic vimentin expression levels in Hct116 and LoVo PDCs after siRNA-SUMO1 transfection. F Nuclear vimentin expression levels in Hct116 and LoVo PDCs after siRNA-SUMO1 transfection. G (a) Total vimentin expression levels in Hct116 PDCs and LoVo PDCs after GA. b Cytoplasmic vimentin expression levels in Hct116 PDCs and LoVo PDCs after GA. c Nuclear vimentin expression levels in Hct116 PDCs and LoVo PDCs after GA. H (a) Vimentin expression levels in Hct116 PDCs without GA, without MG132, or with both GA and MG132 treatment. b Vimentin expression levels in LoVo PDCs without GA, without MG132, and with both GA and MG132 treatments. I (a) Total vimentin expression levels in Hct116 PDCs before and after mutation at the SUMO sites (K373/K439/K445, K373/K439, K439/K445, and K373/K445). b Total vimentin expression levels in LoVo PDCs before and after mutation at the SUMO site (K373/K439/K445, K373/K439, K439/K445, K373 /K445). SUMO small ubiquitin-like modification, PDCs polyploid giant cancer cells with daughter cells, GA ginkgolic acid